Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).

about

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).

Item

http://www.wikidata.org/entity/Q52724325

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Molecular Screening of Small B ...... ancer Consortium (KLCC-13-01).

@en

Molecular Screening of Small B ...... Korean Lung Cancer Consortium

@nl

type

Item

label

Molecular Screening of Small B ...... ancer Consortium (KLCC-13-01).

@en

Molecular Screening of Small B ...... Korean Lung Cancer Consortium

@nl

prefLabel

Molecular Screening of Small B ...... ancer Consortium (KLCC-13-01).

@en

Molecular Screening of Small B ...... Korean Lung Cancer Consortium

@nl

P1476

Molecular Screening of Small B ...... ancer Consortium (KLCC-13-01).

@en

P2093

Bo Mi Ku

http://www.w3.org/2001/XMLSchema#string

Byoung Chul Cho

http://www.w3.org/2001/XMLSchema#string

Eun Kyung Cho

http://www.w3.org/2001/XMLSchema#string

Ho Yun Lee

http://www.w3.org/2001/XMLSchema#string

Hojoong Kim

http://www.w3.org/2001/XMLSchema#string

Jin Seok Ahn

http://www.w3.org/2001/XMLSchema#string

Jong-Mu Sun

http://www.w3.org/2001/XMLSchema#string

Joo-Hang Kim

http://www.w3.org/2001/XMLSchema#string

Keunchil Park

http://www.w3.org/2001/XMLSchema#string

Ki Hyeong Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Comprehensive molecular profiling of lung adenocarcinoma.

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.

Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.

Hot spot mutations in Finnish non-small cell lung cancers.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

P304

148-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4132/JPTM.2018.03.12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29575851

http://www.w3.org/2001/XMLSchema#string

P932

5964289

http://www.w3.org/2001/XMLSchema#string